Instem plc Announcement re: full year results (2888J)

TIDMINS

RNS Number : 2888J

Instem plc

26 April 2022

Instem plc

("Instem", the "Group" or the "Company")

Announcement re: full year results for the year ended 31 December 2021

Instem plc (AIM: INS), a leading provider of IT solutions to the global life sciences market, announces that, at a late stage yesterday evening, the Company's auditors requested further time to complete their work ahead of release of the Company's results for the year ended 31 December 2021 ("FY21"). The results were due to be announced at 07.00am today. The Company understands that the work to be completed is of a routine nature and, accordingly, there will now be a short delay prior to release of the FY21 results.

The Company will provide further updates as appropriate.

For further information, please contact:

 
Instem plc                                  Via Walbrook 
Phil Reason, CEO 
Nigel Goldsmith, CFO 
 
Singer Capital Markets (Nominated Adviser 
 & Joint Broker)                            +44 (0) 20 7496 3000 
Peter Steel 
 Alex Bond 
 Rachel Hayes 
 
Stifel Nicolaus Europe Limited (Joint 
 Broker)                                    +44 (0)20 7710 7600 
Ben Maddison 
Alex Price 
 
Walbrook Financial PR                       +44 (0) 20 7933 8780 
Tom Cooper                                  instem@walbrookpr.com 
Nick Rome 
Nicholas Johnson

About Instem

Instem is a leading provider of IT solutions & services to the life sciences market delivering compelling solutions for Study Management Regulatory Submissions, Clinical Trial Acceleration, and Informatics-based Insight Generation.

Instem solutions are in use by over 700 customers worldwide, including all the largest 25 pharmaceutical companies, enabling clients to bring life enhancing products to market faster. Instem's portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonisation of actionable scientific information.

Instem products and services address aspects of the entire drug development value chain, from discovery through to market launch. Management estimate that over 50% of all drugs on the market have been through some part of Instem's platform at some stage of their development.

   To learn more about Instem solutions and its mission, please visit   www.instem.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NORBQLBLLZLLBBE

(END) Dow Jones Newswires

April 26, 2022 10:06 ET (14:06 GMT)

Instem (LSE:INS)
Historical Stock Chart
From May 2024 to Jun 2024